In addition, we observed activation of SMAD2/3 signaling in imatinib-treated K562 and KU812 CML cells; however, this activation was lower in L523I-expressing cells than in KLC2-WT cells (Fig. 4B,C). This evidence concerns the gene KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive.